# Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

> **NCT06041490** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 88 (estimated)

## Conditions studied

- Liver Transplant; Complications
- Hepatocarcinoma
- Recurrent Osteosarcoma
- High-Risk Cancer

## Interventions

- **DRUG:** multi-kinase inhibitors in combination with bevacizumab

## Key facts

- **NCT ID:** NCT06041490
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09
- **Primary completion:** 2026-06
- **Final completion:** 2027-01
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041490, "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06041490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*